Amphotericin B and its delivery by liposomal and lipid formulations.
In recent years, new formulations of the original amphotericin B preparation (Fungizone) have been devised in order to overcome toxicity problems that frequently occur. These preparations represent an improved method of drug delivery, with an increased therapeutic index and a decrease in toxicity to mammalian cell membranes. The new formulations have different physico-chemical characteristics and differ in pharmacokinetic parameters. Their effects must be compared with conventional amphotericin B to ascertain potential roles in future antifungal therapy.
Gates
C
C
Department of Pharmaceutics, School of Pharmacy, University of London, U.K.
Pinney
R J
RJ
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004337:Drug Carriers; D006801:Humans; D008055:Lipids; D008081:Liposomes
D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D000666:Amphotericin B